Compare Gilead Sciences, Inc. (GILD) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Williams Companies Inc — how do they compare? Gilead Sciences, Inc. trades at $133.43 (market cap $163.51B), while Williams Companies Inc trades at $74.62 (market cap $90.97B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Williams Companies Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| GILD | WMB | |
|---|---|---|
Market Cap | $163.51B | $90.97B |
Sector | Health | Energy |
52-Week High | $155.80 | $79.40 |
52-Week Low | $108.22 | $56.51 |
Enterprise Value | $178.05B | $120.35B |
Dividend Yield | 2.49% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Williams Companies (WMB) trades at $74.76, down 1.61% on the day, with a neutral technical outlook and strong analyst support. The stock shows robust profitability with a 23.4% net margin and 21.95% ROE, while recent news highlights a $5.34 billion Blackstone-led investment for power projects. Cash flow trends improved in 2025, with net cash flow turning positive to $3 million after a 2024 deficit.
WMB presents a favorable long-term outlook with a consensus price target of $85.67 and no sell ratings among analysts. Risks include high debt levels and exposure to natural gas price volatility, but the company's fee-based midstream model and strategic investments in energy infrastructure support dividend growth and earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
